Oral presentation of CARTITUDE-1 study data showcases long-term outcomes after a single infusion of CARVYKTI ® with one-third of patients with relapsed/refractory multiple myeloma progression-free for ...

Multiple myeloma is considered incurable, but a third of patients in a Johnson & Johnson clinical trial have lived without ...

Insilico plans late-stage trials for rentosertib following positive mid-stage safety and efficacy data for idiopathic ...

There's no reason the U.S. can't pick up the pace to match the global clinical research front-runners without compromising ...

Bristol Myers Squibb leapt into the drug industry’s most intense new rivalry on Monday, signing a deal to potentially spend ...

The oncology giant will pay $1.5 billion to co-develop a BioNTech drug that targets the proteins PD-L1 and VEGF, following ...

The BREAKWATER study enrolled patients with newly diagnosed colon cancer that harbors a mutation called BRAF 600E that makes ...

Twenty-eight students in the Jacobs School of Medicine and Biomedical Sciences were honored for outstanding achievements during the University at Buffalo’s 2025 Celebration of Student Academic ...

Personalized medicine—tailoring treatments to individual patients based on their genetic makeup, lifestyle, and environment—is ...

REVEAL GENOMICS, S.L., a biotechnology company advancing precision oncology through biomarker innovation, today announced the ...

LANGHORNE, PA — Savara Inc. (Nasdaq: SVRA) unveiled significant findings from its Phase 3 IMPALA-2 clinical trial of ...